FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4366448910> ?p ?o ?g. }

• W4366448910 abstract "Abstract Background Endeavors in molecular characterization of breast cancer paved the way to endocrine therapies in ER+/HER2- breast cancer, increasing response rates. Despite that, taxane-based neoadjuvant chemotherapy is still a cornerstone for breast-conserving surgery and complete tumor resection in locally advanced cancers with high recurrence risk. Nonetheless, chemoresistance risk is high. Therefore, predicting unresponsiveness to chemotherapy is a significant task to prevent futile toxicities in patients. Despite several multi-gene assays being used for this purpose, their development as prognostic assays limits predictive strength, leading to discordant results. Moreover, high costs impediment their use in developing countries. For global health equity, robust predictors that can be cost-effectively incorporated into routine clinical management are essential. Methods To identify robust predictors in ER+/HER2- breast cancer, we performed comprehensive profiling and gene set enrichment analysis in 5 GEO datasets. To validate the potential predictors we performed ROC analysis, KM-survival analysis and Cox Proportional Hazards Regression in two validation cohorts. To compare predictive power of potential predictors with the genes in the benchmark signatures we performed gene correlation and signature analysis in TCGA dataset. Results Gene expression and gene set enrichment analysis revealed 63 upregulated genes and the enrichment of CTNNB1-related oncogenic signatures in non-responsive patients. We validated the upregulation and predictive strength of 18 genes, all exhibiting higher predictive powers for residual disease and higher specificities for ER+/HER2- breast cancers compared to one of the benchmark multi-gene assays. Cox Proportional Hazards Regression in three different treatment arms (neoadjuvant chemotherapy, endocrine therapy, and no systemic treatment) put forth PTCH1 and CTNNB1 as key predictors, with hazard ratios over 1.5, and 1.6 respectively in the univariate and multivariate models. Conclusions Our results strongly suggest that PTCH1 and CTNNB1 can be used as robust and cost-effective predictors in developing countries to guide decisions on chemotherapy in ER+/HER2- breast cancer patients with a high risk of recurrence. The dual function of PTCH1 as a multidrug efflux pump and a hedgehog receptor, and the active involvement of CTNNB1 in breast cancer strongly indicate that PTCH1 and CTNNB1 can be potential drug targets to overcome chemoresistance in ER+/HER2- breast cancer patients." @default.
• W4366448910 created "2023-04-22" @default.
• W4366448910 creator A5051040995 @default.
• W4366448910 date "2023-04-19" @default.
• W4366448910 modified "2023-10-01" @default.
• W4366448910 title "PTCH1 and CTNNB1 emerge as pivotal predictors of resistance to neoadjuvant chemotherapy in ER+/HER2- breast cancer" @default.
• W4366448910 cites W2089678662 @default.
• W4366448910 cites W2887132021 @default.
• W4366448910 cites W3003620669 @default.
• W4366448910 cites W3128646645 @default.
• W4366448910 cites W4211123279 @default.
• W4366448910 doi "https://doi.org/10.21203/rs.3.rs-2820986/v1" @default.
• W4366448910 hasPublicationYear "2023" @default.
• W4366448910 type Work @default.
• W4366448910 citedByCount "0" @default.
• W4366448910 crossrefType "posted-content" @default.
• W4366448910 hasAuthorship W4366448910A5051040995 @default.
• W4366448910 hasBestOaLocation W43664489101 @default.
• W4366448910 hasConcept C104317684 @default.
• W4366448910 hasConcept C121608353 @default.
• W4366448910 hasConcept C126322002 @default.
• W4366448910 hasConcept C143998085 @default.
• W4366448910 hasConcept C150194340 @default.
• W4366448910 hasConcept C2776694085 @default.
• W4366448910 hasConcept C2777511904 @default.
• W4366448910 hasConcept C2779733811 @default.
• W4366448910 hasConcept C50382708 @default.
• W4366448910 hasConcept C530470458 @default.
• W4366448910 hasConcept C55493867 @default.
• W4366448910 hasConcept C71924100 @default.
• W4366448910 hasConcept C86803240 @default.
• W4366448910 hasConceptScore W4366448910C104317684 @default.
• W4366448910 hasConceptScore W4366448910C121608353 @default.
• W4366448910 hasConceptScore W4366448910C126322002 @default.
• W4366448910 hasConceptScore W4366448910C143998085 @default.
• W4366448910 hasConceptScore W4366448910C150194340 @default.
• W4366448910 hasConceptScore W4366448910C2776694085 @default.
• W4366448910 hasConceptScore W4366448910C2777511904 @default.
• W4366448910 hasConceptScore W4366448910C2779733811 @default.
• W4366448910 hasConceptScore W4366448910C50382708 @default.
• W4366448910 hasConceptScore W4366448910C530470458 @default.
• W4366448910 hasConceptScore W4366448910C55493867 @default.
• W4366448910 hasConceptScore W4366448910C71924100 @default.
• W4366448910 hasConceptScore W4366448910C86803240 @default.
• W4366448910 hasLocation W43664489101 @default.
• W4366448910 hasOpenAccess W4366448910 @default.
• W4366448910 hasPrimaryLocation W43664489101 @default.
• W4366448910 hasRelatedWork W1570801813 @default.
• W4366448910 hasRelatedWork W1980408514 @default.
• W4366448910 hasRelatedWork W2092771806 @default.
• W4366448910 hasRelatedWork W2367105124 @default.
• W4366448910 hasRelatedWork W2379009234 @default.
• W4366448910 hasRelatedWork W2388730008 @default.
• W4366448910 hasRelatedWork W2792941486 @default.
• W4366448910 hasRelatedWork W2974120029 @default.
• W4366448910 hasRelatedWork W3030794620 @default.
• W4366448910 hasRelatedWork W3175662144 @default.
• W4366448910 isParatext "false" @default.
• W4366448910 isRetracted "false" @default.
• W4366448910 workType "article" @default.